Literature DB >> 30104268

Minocycline Has No Clear Role in the Treatment of Mycobacterium abscessus Disease.

Mike M Ruth1, Jasper J N Sangen1, Lian J Pennings1, Jodie A Schildkraut1, Wouter Hoefsloot2, Cecile Magis-Escurra2, Heiman F L Wertheim1, Jakko van Ingen3.   

Abstract

Mycobacterium abscessus causes a difficult-to-treat pulmonary disease (MAb-PD). After initial intravenous treatment, minocycline is recommended in the oral continuation phase of treatment. We determined the MICs, synergy, and time-kill kinetics of minocycline against M. abscessus With MICs of 8 to 512 mg/liter, rapid emergence of tolerance in time-kill assays, and no synergy with other drugs used to treat MAb-PD, minocycline appears ineffective against M. abscessus These in vitro data question its role as a MAb-PD treatment modality.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Mycobacterium abscessus; minocycline; pharmacokinetics

Mesh：

Substances：

Year:  2018        PMID： 30104268      PMCID： PMC6153809          DOI： 10.1128/AAC.01208-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

1.  Synergy, antagonism, and what the chequerboard puts between them.

Authors:  F C Odds
Journal:  J Antimicrob Chemother       Date:  2003-06-12       Impact factor: 5.790

Review 2.  Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin.

Authors:  G L French
Journal:  J Antimicrob Chemother       Date:  2006-10-13       Impact factor: 5.790

3.  Inhibition of the β-Lactamase BlaMab by Avibactam Improves the In Vitro and In Vivo Efficacy of Imipenem against Mycobacterium abscessus.

Authors:  Anne-Laure Lefebvre; Vincent Le Moigne; Audrey Bernut; Carole Veckerlé; Fabrice Compain; Jean-Louis Herrmann; Laurent Kremer; Michel Arthur; Jean-Luc Mainardi
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

4.  Time-kill kinetics of antibiotics active against rapidly growing mycobacteria.

Authors:  Beatriz E Ferro; Jakko van Ingen; Melanie Wattenberg; Dick van Soolingen; Johan W Mouton
Journal:  J Antimicrob Chemother       Date:  2014-10-25       Impact factor: 5.790

5.  Uptake of antibiotics by human alveolar macrophages.

Authors:  W L Hand; R W Corwin; T H Steinberg; G D Grossman
Journal:  Am Rev Respir Dis       Date:  1984-06

Review 6.  Mycobacterium abscessus: a new antibiotic nightmare.

Authors:  Rachid Nessar; Emmanuelle Cambau; Jean Marc Reyrat; Alan Murray; Brigitte Gicquel
Journal:  J Antimicrob Chemother       Date:  2012-01-30       Impact factor: 5.790

7.  Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline, and doxycycline against isolates of nontuberculous mycobacteria.

Authors:  Richard J Wallace; Barbara A Brown-Elliott; Christopher J Crist; Linda Mann; Rebecca W Wilson
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

8.  In vitro efficacy of imipenem in combination with six antimicrobial agents against Mycobacterium abscessus.

Authors:  Tomomitsu Miyasaka; Hiroyuki Kunishima; Mayumi Komatsu; Kiyoko Tamai; Kotaro Mitsutake; Keiji Kanemitsu; Yoshiharu Ohisa; Hideji Yanagisawa; Mitsuo Kaku
Journal:  Int J Antimicrob Agents       Date:  2007-07-09       Impact factor: 5.283

9.  Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium.

Authors:  Josephine M Bryant; Dorothy M Grogono; Daniela Rodriguez-Rincon; Isobel Everall; Karen P Brown; Pablo Moreno; Deepshikha Verma; Emily Hill; Judith Drijkoningen; Peter Gilligan; Charles R Esther; Peadar G Noone; Olivia Giddings; Scott C Bell; Rachel Thomson; Claire E Wainwright; Chris Coulter; Sushil Pandey; Michelle E Wood; Rebecca E Stockwell; Kay A Ramsay; Laura J Sherrard; Timothy J Kidd; Nassib Jabbour; Graham R Johnson; Luke D Knibbs; Lidia Morawska; Peter D Sly; Andrew Jones; Diana Bilton; Ian Laurenson; Michael Ruddy; Stephen Bourke; Ian Cjw Bowler; Stephen J Chapman; Andrew Clayton; Mairi Cullen; Thomas Daniels; Owen Dempsey; Miles Denton; Maya Desai; Richard J Drew; Frank Edenborough; Jason Evans; Jonathan Folb; Helen Humphrey; Barbara Isalska; Søren Jensen-Fangel; Bodil Jönsson; Andrew M Jones; Terese L Katzenstein; Troels Lillebaek; Gordon MacGregor; Sarah Mayell; Michael Millar; Deborah Modha; Edward F Nash; Christopher O'Brien; Deirdre O'Brien; Chandra Ohri; Caroline S Pao; Daniel Peckham; Felicity Perrin; Audrey Perry; Tania Pressler; Laura Prtak; Tavs Qvist; Ali Robb; Helen Rodgers; Kirsten Schaffer; Nadia Shafi; Jakko van Ingen; Martin Walshaw; Danie Watson; Noreen West; Joanna Whitehouse; Charles S Haworth; Simon R Harris; Diane Ordway; Julian Parkhill; R Andres Floto
Journal:  Science       Date:  2016-11-11       Impact factor: 47.728

10.  Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects.

Authors:  Mark H Gotfried; Karolyn Horn; Lynne Garrity-Ryan; Stephen Villano; Evan Tzanis; Surya Chitra; Amy Manley; S Ken Tanaka; Keith A Rodvold
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191
View more
  5 in total

Review 1.  Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Drug Treatment of Non-Tuberculous Mycobacteria in Cystic Fibrosis.

Authors:  Andrew Burke; Daniel Smith; Chris Coulter; Scott C Bell; Rachel Thomson; Jason A Roberts
Journal:  Clin Pharmacokinet       Date:  2021-05-13       Impact factor: 5.577

2.  Mycobacterium abscessus Associated Peritonitis with CAPD Successfully Treated Using a Linezolid and Tedizolid Containing Regimen Suggested Immunomodulatory Effects.

Authors:  Masafumi Seki; Yasuhiro Kamioka; Kazuki Takano; Haruka Imai; Mai Shoji; Maya Hariu; Yukari Kabutoya; Yuji Watanabe
Journal:  Am J Case Rep       Date:  2020-06-29

3.  In Vitro Susceptibility of Mycobacterium abscessus and Mycobacterium fortuitum Isolates to 30 Antibiotics.

Authors:  Yaojie Shen; Xuyang Wang; Jialin Jin; Jing Wu; Xuelian Zhang; Jiazhen Chen; Wenhong Zhang
Journal:  Biomed Res Int       Date:  2018-12-30       Impact factor: 3.411

4.  Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?

Authors:  Mike Marvin Ruth; Valerie A C M Koeken; Lian J Pennings; Elin M Svensson; Heiman F L Wertheim; Wouter Hoefsloot; Jakko van Ingen
Journal:  J Antimicrob Chemother       Date:  2020-03-01       Impact factor: 5.790

5.  Inhaled tigecycline is effective against Mycobacterium abscessus in vitro and in vivo.

Authors:  Camron Pearce; Mike M Ruth; Lian J Pennings; Heiman F L Wertheim; Amanda Walz; Wouter Hoefsloot; Carolien Ruesen; Juan Muñoz Gutiérrez; Mercedes Gonzalez-Juarrero; Jakko van Ingen
Journal:  J Antimicrob Chemother       Date:  2020-07-01       Impact factor: 5.790
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.